Research advances in post-sinusoidal non-cirrhotic portal hypertension

Huiting CHEN; Yongjian ZHOU

doi:10.3969/j.issn.1001-5256.2022.07.004

Volume 38 Issue 7

Jul. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(7): 1469-1473

PDF( 1852 KB)

Research advances in post-sinusoidal non-cirrhotic portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.07.004

Huiting CHEN^{1, 2, 3},
Yongjian ZHOU^{1, 2, 3
,
,
,}

1.
Department of Gastroenterology, Guangzhou First People's Hospital, Guangzhou 510180, China
2.
Guangzhou Digestive Disease Center, Guangzhou 510180, China
3.
Department of Gastroenterology, The Second Affiliated Hospital of South China University of Technology, Guangzhou 510180, China

Research funding:

National Natural Science Foundation of China (81970507);

National Natural Science Foundation of China (82170585);

Natural Science Foundation of Guangdong Province (2020A1515010100);

Natural Science Foundation of Guangdong Province (2021A1515011290);

Technology Planning Project of Guangzhou City (201904010132);

Technology Planning Project of Guangzhou City (202102010023);

Guangdong Medical Science and Research Foundation (A2020411);

Guangzhou High Technology Project (2019GX05);

Project of Key Medical Discipline in Guangzhou (2021-2023)

More Information

Corresponding author: ZHOU Yongjian, eyzhouyongjian@scut.edu.cn(ORCID: 0000-0002-4036-4592)
Received Date: 2022-04-20
Accepted Date: 2022-05-22
Published Date: 2022-07-20

Abstract

Abstract

Portal hypertension (PH) is defined as the pathological increase in pressure in the portal venous system. The most common cause of PH is liver cirrhosis, but it is also observed in patients without liver cirrhosis, which is called non-cirrhotic portal hypertension. Non-cirrhotic portal hypertension can be classified in prehepatic, intrahepatic, and posthepatic types depending on the site of involvement, and the intrahepatic type can be further divided into presinusoidal, sinusoidal, and post-sinusoidal types. This article summarizes the features of posthepatic and post-sinusoidal portal hypertension, discusses in detail the different classifications of Budd-Chiari syndrome and hepatic sinusoidal obstruction syndrome, and briefly introduces the research advances in the clinical manifestations, pathogenesis, diagnosis, and treatment of these diseases.
- Noncirrhotic Portal Hypertension,
- Budd-Chiari Syndrome,
- Hepatic Veno-Occlusive Disease

FullText(HTML)

References(23)

References

[1]	MAROZAS M, ZYKUS R, SAKALAUSKAS A, et al. Noninvasive evaluation of portal hypertension using a supervised learning technique[J]. J Healthc Eng, 2017, 2017: 6183714. DOI: 10.1155/2017/6183714.
[2]	MAHMOUD AE, ELIAS E, BEAUCHAMP N, et al. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis[J]. Gut, 1997, 40(6): 798-800. DOI: 10.1136/gut.40.6.798.
[3]	PLESSIER A, VALLA DC. Budd-Chiari syndrome[J]. Semin Liver Dis, 2008, 28(3): 259-269. DOI: 10.1055/s-0028-1085094.
[4]	BOLONDI L, GAIANI S, LI BASSI S, et al. Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound[J]. Gastroenterology, 1991, 100(5 Pt 1): 1324-1331.
[5]	SOYER P, RABENANDRASANA A, BARGE J, et al. MRI of Budd-Chiari syndrome[J]. Abdom Imaging, 1994, 19(4): 325-329. DOI: 10.1007/BF00198189.
[6]	XU P, LYU L, SAMI MU, et al. Diagnostic accuracy of magnetic resonance angiography for Budd-Chiari syndrome: A meta-analysis[J]. Exp Ther Med, 2018, 16(6): 4873-4878. DOI: 10.3892/etm.2018.6764.
[7]	TANG TJ, BATTS KP, de GROEN PC, et al. The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome[J]. J Hepatol, 2001, 35(3): 338-343. DOI: 10.1016/s0168-8278(01)00131-3.
[8]	RAUTOU PE, MOUCARI R, CAZALS-HATEM D, et al. Levels and initial course of serum alanine aminotransferase can predict outcome of patients with Budd-Chiari syndrome[J]. Clin Gastroenterol Hepatol, 2009, 7(11): 1230-1235. DOI: 10.1016/j.cgh.2009.06.011.
[9]	LI Z, WANG L, YI F, et al. Rapid development of gingival bleeding after rivaroxaban in a patient with Budd-Chiari syndrome[J]. Liver Int, 2021, 41(9): 2236-2237. DOI: 10.1111/liv.15021.
[10]	DARWISH MURAD S, PLESSIER A, HERNANDEZ-GUERRA M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome[J]. Ann Intern Med, 2009, 151(3): 167-175. DOI: 10.7326/0003-4819-151-3-200908040-00004.
[11]	HAN G, QI X, ZHANG W, et al. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center[J]. Radiology, 2013, 266(2): 657-667. DOI: 10.1148/radiol.12120856.
[12]	MENTHA G, GIOSTRA E, MAJNO PE, et al. Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres[J]. J Hepatol, 2006, 44(3): 520-528. DOI: 10.1016/j.jhep.2005.12.002.
[13]	Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing)[J]. J Clin Hepatol, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003. 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年, 南京)[J]. 临床肝胆病杂志, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.
[14]	YANG M, RUAN J, GAO H, et al. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans[J]. Arch Toxicol, 2017, 91(12): 3913-3925. DOI: 10.1007/s00204-017-2013-y.
[15]	KERNAN N, RICHARDSON P, TRIPLETT B, et al. Efficacy and safety of defibrotide (DF) to treat hepatic veno-occlusive di sease/ sinusoidal obstruction svndrome (VOD/SOS) after primarv chemotherapv(CT): A post hocanalysis of final data[J]. J Clin Oncol, 2017, 35(15): 10513. DOI: 10.1200/jco.2017.35.15_supp.10513.
[16]	XIA Y, QIN H, YANG J. Hepatic veno-occlusive disease development in the hematopoietic stem cell transplantation patients: incidence and associated risk factors, a meta-analysis[J]. Eur J Gastroenterol Hepatol, 2021, 33(6): 872-884. DOI: 10.1097/MEG.0000000000001802.
[17]	MOHTY M, MALARD F, ABECASSIS M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation[J]. Bone Marrow Transplant, 2016, 51(7): 906-912. DOI: 10.1038/bmt.2016.130.
[18]	DEVARBHAVI H, SINGH R, PATE M, et al. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury[J]. J Gastroentero Hepatol, 2013, 28(1): 161-167. DOI: 10.1111/j.1440-1746.2012.07279.x.
[19]	KIM J, JUNG Y. Radiation—induced liver disease: Current understanding and future perspectives[J]. Exp Mol Med, 2017, 49(7): e359. DOI: 10.1038/emm.2017.85.
[20]	YOON JH, MIN GJ, PARK SS, et al. Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1[J]. Bone Marrow Transplant, 2021, 56(7): 1603-1613. DOI: 10.1038/s41409-021-01215-y.
[21]	MOHTY M, MALARD F, ABECASIS M, et al. Prophylactic, preemptive, and curative treatment for sinusoia-l obstruction syndrome/venoocclusive disease in adult patients: a position statement from an international expert group[J]. Bone Marrow Transplant, 2020, 55(3): 485-495. DOI: 10.1038/s41409-019-0705-z.
[22]	DIGNAN FL, WYNN RF, HADZIC N, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation[J]. Br J Haematol, 2013, 163(4): 444-457. DOI: 10.1111/bjh.12558.
[23]	PICOD A, BONNIN A, BATTIPAGLIA G, et al. Defibrotide for sinusoidal obstruction syndrome/veno-occlusive disease prophylaxis in high-risk adult patients: a single-center experience study[J]. Biol Blood Marrow Transplant, 2018, 24(7): 1471-1475. DOI: 10.1016/j.bbmt.2018.02.015.

Relative Articles

[1]	Yu WANG, Xuebing YAN. Advances in phase Ⅲ drug studies on the pipeline in nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2022, 38(6): 1398-1401. doi: 10.3969/j.issn.1001-5256.2022.06.037
[2]	Yingshuo HUANG, Wei WEI, Xiaofei TONG, Yameng SUN, Jianxiong ZHANG, Ruihua DONG, Jidong JIA, Hong YOU. Clinical trial protocols of new drugs for nonalcoholic steatohepatitis: A systematic review[J]. Journal of Clinical Hepatology, 2022, 38(4): 798-804. doi: 10.3969/j.issn.1001-5256.2022.04.012
[3]	Ziming AN, Qin FENG. Magnetic resonance imaging-proton density fat fraction: A potential surrogate endpoint for nonalcoholic steatohepatitis clinical trials[J]. Journal of Clinical Hepatology, 2021, 37(6): 1445-1448. doi: 10.3969/j.issn.1001-5256.2021.06.047
[4]	Yingshuo HUANG, Ruihua DONG, Hong YOU. Difficulties and challenges in the clinical trial of new drugs for nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1948-1952. doi: 10.3969/j.issn.1001-5256.2021.08.044
[5]	QIAN ShuaiJie, GU JingYue, GAO JinHang, TONG Huan. Advances in therapeutic drugs for nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2826-2830. doi: 10.3969/j.issn.1001-5256.2020.12.039
[6]	Song QingLian, Tan YuE, Liu JingJing, Yuan BeiBei, Li Min, He LiQin, Dai GuangRong. Establishment of a rat model of nonalcoholic steatohepatitis and histopathological changes of the pancreas and the kidney[J]. Journal of Clinical Hepatology, 2020, 36(1): 140-144. doi: 10.3969/j.issn.1001-5256.2020.01.031
[7]	Zhang LiHui, Zhang JianBo, Zhao WenXia. Effect of Huatan Qushi Huoxue prescription on the key proteins of the ADPN/PI3K/Akt signaling pathway in rats with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 835-839. doi: 10.3969/j.issn.1001-5256.2020.04.025
[8]	Zhou QingLi, Xu ZhenYuan, Zhang SuYan, Shi AnHua, Zhang ShunZhen. The role of the NOD-like receptor family, pyrin domain-containing protein 3 inflammasome in nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1380-1383. doi: 10.3969/j.issn.1001-5256.2019.06.045
[9]	Chen Jun, Li LiangPing, Fu WanZhi. Value of microparticles in the diagnosis of nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2019, 35(9): 2026-2031. doi: 10.3969/j.issn.1001-5256.2019.09.028
[10]	Chang Yue, Li Hai. The role of gut microbiota in the development and progression of nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2018, 34(6): 1343-1346. doi: 10.3969/j.issn.1001-5256.2018.06.045
[11]	Chen Ye, Wu JinLu, Pan WenTing, Li HaiYing. Research advances in the mechanism of fructose-induced nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2449-2452. doi: 10.3969/j.issn.1001-5256.2017.12.044
[12]	Zhao WenXia, Yan Le, Shao MingYi, Zhang LiHui. Effect of Huatan Qushi Huoxue prescription on the ADPN/AMPK/ACC signaling pathway in rats with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2017, 33(5): 932-936. doi: 10.3969/j.issn.1001-5256.2017.05.029
[13]	Wan Yan, Chang JianBo, Bai YanXia, Li QianNan, Dai GuangRong. Significance of serological markers in diagnosis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(5): 963-968. doi: 10.3969/j.issn.1001-5256.2017.05.037
[14]	Mao YiMin. Clinical trials of investigational new drugs for nonalcoholic steatohepatitis:challenges in design and practice[J]. Journal of Clinical Hepatology, 2017, 33(12): 2292-2295. doi: 10.3969/j.issn.1001-5256.2017.12.007
[15]	Hu MengQi, Xu YouQing, Zhang Tao, Xu HongTuan. Research advances in noninvasive diagnostic methods for nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2017, 33(12): 2288-2291. doi: 10.3969/j.issn.1001-5256.2017.12.006
[16]	Zhu ChuanLong, Wang Kun, Gao RenDao. Clinical application of noninvasive diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 332-336. doi: 10.3969/j.issn.1001-5256.2015.03.004
[17]	Yang Shuo, Lu: Dong, Xu YouQing. Research advances in noninvasive diagnosis of nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2013, 29(12): 901-904. doi: 10.3969/j.issn.1001-5256.2013.12.007
[18]	Cai WeiMin. Noninvasive diagnosis of significant liver fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(7): 762-767.
[19]	Huang Ning, Wu WanChun. The effect of low iron loads on Nonalcoholic Steatohepatitis in rats[J]. Journal of Clinical Hepatology, 2009, 25(6): 427-430.
[20]	Xu Hui, Wen QinSheng, Wang XuXia, Zhang YaFei, Li Jun, Gu BingQuan. The effect of cimetidine on the blood sugar, serum insulin and other indexes in NASH rats[J]. Journal of Clinical Hepatology, 2007, 23(2): 112-114.

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 盖楠，张娇. 非酒精性脂肪性肝炎患者血清CK18和FGF-21水平变化及临床意义探讨. 社区医学杂志. 2022(18): 1018-1021 .
Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (787) PDF downloads(121)

Research advances in post-sinusoidal non-cirrhotic portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.07.004

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(3)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in post-sinusoidal non-cirrhotic portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.07.004

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(3)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content